Climb Bio (NASDAQ:CLYM) outlined its strategy and upcoming clinical milestones during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, with Chief Medical Officer Edgar ...
Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune ...
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...
Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...
Janux Therapeutics Inc. (NASDAQ: JANX) is one of the best cancer stocks to invest in now. On February 17, Janux Therapeutics Inc. (NASDAQ:JANX) commenced patient dosing in the Phase 1 study of JANX011 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results